{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:45:10Z","timestamp":1778931910816,"version":"3.51.4"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00521","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T07:53:26Z","timestamp":1542095606000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme"],"prefix":"10.3389","volume":"8","author":[{"given":"Christopher","family":"Chin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma S.","family":"Lunking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagi G.","family":"Ayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jamaneurol.2014.1701","article-title":"Emerging therapies for glioblastoma","volume":"71","author":"Thomas","year":"2014","journal-title":"JAMA Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"Glioblastoma: overview of disease and treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin J Oncol Nurs."},{"key":"B3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1182\/blood-2011-10-386482","article-title":"Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer","volume":"119","author":"Yao","year":"2012","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2018.1488254","article-title":"(18)F-FDG PET\/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors","author":"Castello","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00432-011-1003-3","article-title":"Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial","volume":"137","author":"Butts","year":"2011","journal-title":"J Cancer Res Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat Rev"},{"key":"B9","first-page":"201","article-title":"Immunotherapy for glioblastoma:on the sidelines or in the game?","volume":"24","author":"Reardon","year":"2017","journal-title":"Discov Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"18577","DOI":"10.18632\/oncotarget.14612","article-title":"Advances in epigenetic glioblastoma therapy","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"B11","year":"","journal-title":"Combination of Immunization and Radiotherapy for Recurrent GBM (InSituVac1)"},{"key":"B12","year":"","journal-title":"Basiliximab in Treating Patients with Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia"},{"key":"B13","year":"","journal-title":"Vaccine Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme"},{"key":"B14","year":"","journal-title":"Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme"},{"key":"B15","year":"","journal-title":"A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)"},{"key":"B16","year":"","journal-title":"Tremelimumab and Durvalumabin Combination or Alonein Treating Patients with Recurrent Malignant Glioma"},{"key":"B17","year":"","journal-title":"Pembrolizumab and Vorinostat Combined with Temozolomide for Newly Diagnosed Glioblastoma"},{"key":"B18","year":"","journal-title":"Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients"},{"key":"B19","year":"","journal-title":"A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma"},{"key":"B20","year":"","journal-title":"Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients with Brain Tumors"},{"key":"B21","year":"","journal-title":"Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)"},{"key":"B22","year":"","journal-title":"A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated with Chemoradiation or Immunotherapy"},{"key":"B23","year":""},{"key":"B24","first-page":"4247","article-title":"Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors","volume":"9","author":"Heimberger","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B25","year":""},{"key":"B26","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","article-title":"Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma","volume":"28","author":"Sampson","year":"2010","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1593\/neo.111338","article-title":"Expression of EGFRvIII in glioblastoma: prognostic significance revisited","volume":"13","author":"Montano","year":"2011","journal-title":"Neoplasia"},{"key":"B28","year":""},{"key":"B29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e318215e300","article-title":"Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy","volume":"34","author":"Fadul","year":"2011","journal-title":"J Immunother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"N","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrclinonc.2017.122","article-title":"Glioblastoma subtypes revisited","volume":"14","author":"Sidaway","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","article-title":"Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment","volume":"32","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.aai8478","article-title":"Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq","author":"Venteicher","year":"2017","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2018.07.006","article-title":"Comparison of glioblastoma (GBM) molecular classification methods","author":"Lee","year":"2018","journal-title":"Semin Cancer Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mrfmmm.2018.06.002","article-title":"Improved molecular karyotyping in glioblastoma","volume":"811","author":"Burbulis","year":"2018","journal-title":"Mutat Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"91779","DOI":"10.18632\/oncotarget.21586","article-title":"Recurrent glioma clinical trial, CHECKMATE-143: the game is not over yet","volume":"8","author":"Filley","year":"2017","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","article-title":"T-cell exhaustion: characteristics, causes and conversion","volume":"129","author":"Yi","year":"2010","journal-title":"Immunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox168.475","article-title":"IMMU-16","author":"Park","year":"2017","journal-title":"Neuro Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1158\/0008-5472.CAN-17-3714","article-title":"Computational characterization of suppressive immune microenvironments in glioblastoma","volume":"78","author":"Luoto","year":"2018","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/path.4282","article-title":"Using the molecular classification of glioblastoma to inform personalized treatment","volume":"232","author":"Adriana","year":"2014","journal-title":"J Pathol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1448329","DOI":"10.1080\/2162402X.2018.1448329","article-title":"The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma","volume":"7","author":"DiDomenico","year":"2018","journal-title":"Oncoimmunology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.nec.2009.08.012","article-title":"The role of tregs in glioma-mediated immunosuppression: potential target for intervention","volume":"21","author":"Humphries","year":"2010","journal-title":"Neurosurg Clin N Am"},{"key":"B44","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1172\/JCI22685","article-title":"Immune recognition of self in immunity against cancer","volume":"114","author":"Houghton","year":"2004","journal-title":"J Clin Invest."},{"key":"B45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4137\/GEG.S12270","article-title":"Use of epigenetic drugs in disease: an overview","volume":"6","author":"Heerboth","year":"2014","journal-title":"Genet Epigenet."},{"key":"B46","doi-asserted-by":"publisher","first-page":"E2659","DOI":"10.3390\/ijms18122659","article-title":"lncrna structural characteristics in epigenetic regulation","volume":"18","author":"Wang","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/bies.201100084","article-title":"Long non-coding RNA modifies chromatin","volume":"33","author":"Saxena","year":"2011","journal-title":"BioEssays"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1002\/jcp.26568","article-title":"Long noncoding RNAs in cancer-immunity cycle","volume":"233","author":"Yu","year":"2018","journal-title":"J Cell Physiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1055\/s-0038-1655549","article-title":"Prospective series of nine long noncoding rnas associated with survival of patients with glioblastoma","volume":"79","author":"Lei","year":"2018","journal-title":"J Neurol Surg A Cent Eur Neurosurg"},{"key":"B50","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gene.2016.06.024","article-title":"Analysis of dysregulated long non-coding RNA expressions in glioblastoma cells","volume":"590","author":"Balci","year":"2016","journal-title":"Gene"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3390\/cancers7030843","article-title":"Long non-coding RNAs: the key players in glioma pathogenesis","volume":"7","author":"Kiang","year":"2015","journal-title":"Cancers"},{"key":"B52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12943-018-0822-0","article-title":"Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme","volume":"17","author":"Tan","year":"2018","journal-title":"Mol Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2850657","DOI":"10.1155\/2018\/2850657","article-title":"HOTAIR Is a potential novel biomarker in patients with congenital heart diseases","volume":"2018","author":"Jiang","year":"2018","journal-title":"Biomed Res Int."},{"key":"B54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/mc.22739","article-title":"Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma","volume":"57","author":"Shen","year":"2018","journal-title":"Mol Carcinog."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2017.3901","article-title":"HOTAIR upregulates an 18-gene cell cycle-related mRNA network in glioma","author":"Huang","year":"2017","journal-title":"Int J Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"8353","DOI":"10.18632\/oncotarget.3229","article-title":"HOTAIR is a therapeutic target in glioblastoma","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarge"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1159\/000489110","article-title":"LncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt\/Ss-catenin signaling pathway","volume":"46","author":"Xiao","year":"2018","journal-title":"Cell Physiol Biochem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"15740","DOI":"10.18632\/oncotarget.24597","article-title":"The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma","volume":"9","author":"Xavier-Magalhaes","year":"2018","journal-title":"Oncotarget"},{"key":"B59","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.1073\/pnas.1424220112","article-title":"The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation","volume":"112","author":"Pastori","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.7759\/cureus.620","article-title":"bromodomain inhibitor review: bromodomain and extra-terminal family protein inhibitors as a potential new therapy in central nervous system tumors","volume":"8","author":"Wadhwa","year":"2016","journal-title":"Cureus"},{"key":"B61","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/annonc\/mdy050","article-title":"Epigenetic modifiers as new immunomodulatory therapies in solid tumours","volume":"29","author":"Aspeslagh","year":"2018","journal-title":"Ann Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-018-0619-z","article-title":"A cytoplasmic long noncoding RNA LINC00470 as a new AKT activator to mediate glioblastoma cell autophagy","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4103\/0019-5154.160511","article-title":"Vorinostat-an overview","volume":"60","author":"Bubna","year":"2015","journal-title":"Indian J Dermatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1038\/sj.leu.2404796","article-title":"CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine","volume":"21","author":"Raj","year":"2007","journal-title":"Leukemia"},{"key":"B65","year":"","journal-title":"Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes"},{"key":"B66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-017-0358-y","article-title":"Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy","volume":"9","author":"Mazzone","year":"2017","journal-title":"Clin Epigenet."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00521\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T07:53:28Z","timestamp":1542095608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00521\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":66,"alternative-id":["10.3389\/fonc.2018.00521"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00521","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"article-number":"521"}}